Targeting chemotherapy to advanced bladder cancer patients most likely to benefit.

about

Contribution of tumoral and host solute carriers to clinical drug response.

P2860

Q35946876-2D64DF3A-0EBD-41B9-A932-2B43D2DDF523

P2860

Targeting chemotherapy to advanced bladder cancer patients most likely to benefit.

Item

http://www.wikidata.org/entity/Q39901909

description

2010 nî lūn-bûn

@nan

2010年の論文

@ja

2010年学术文章

@wuu

2010年学术文章

@zh-cn

2010年学术文章

@zh-hans

2010年学术文章

@zh-my

2010年学术文章

@zh-sg

2010年學術文章

@yue

2010年學術文章

@zh

2010年學術文章

@zh-hant

name

Targeting chemotherapy to advanced bladder cancer patients most likely to benefit.

@en

Targeting chemotherapy to advanced bladder cancer patients most likely to benefit.

@nl

type

Item

label

Targeting chemotherapy to advanced bladder cancer patients most likely to benefit.

@en

Targeting chemotherapy to advanced bladder cancer patients most likely to benefit.

@nl

prefLabel

Targeting chemotherapy to advanced bladder cancer patients most likely to benefit.

@en

Targeting chemotherapy to advanced bladder cancer patients most likely to benefit.

@nl

P1476

Targeting chemotherapy to advanced bladder cancer patients most likely to benefit

@en

P2093

Freddie C Hamdy

http://www.w3.org/2001/XMLSchema#string

P2860

When should an effective treatment be used? Derivation of the threshold number needed to treat and the minimum event rate for treatment.

Optimal management of high-risk T1G3 bladder cancer: a decision analysis

An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guérin for non-muscle-invasive bladder cancer.

Neoadjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis.

Systemic chemotherapy for advanced bladder cancer: update and controversies.

Clinical benefits of a multivariate prediction model for bladder cancer: a decision analytic approach.

Radical cystectomy for bladder cancer today--a homogeneous series without neoadjuvant therapy.

Longer wait times increase overall mortality in patients with bladder cancer.

Neurofuzzy modeling to determine recurrence risk following radical cystectomy for nonmetastatic urothelial carcinoma of the bladder.

Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer.

P304

193-196

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2217/FON.09.178

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

James Catto

P577

2010-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

20146577

http://www.w3.org/2001/XMLSchema#string

Targeting chemotherapy to advanced bladder cancer patients most likely to benefit.

about

P2860

P2860

Targeting chemotherapy to advanced bladder cancer patients most likely to benefit.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698